ПЕРСПЕКТИВИ ВИКОРИСТАННЯ ЛЕКТИНІВ ДЛЯ ДІАГНОСТИКИ І ЛІКУВАННЯ ЗЛОЯКІСНИХ НОВОУТВОРЕНЬ
Ключові слова:
лектини, глікокон’югати мембран пухлинних клітин, диференційна діагностика, моніторинг агресивності пухлини, цитотоксична активність, інгібування проліферації.Анотація
Мета огляду — узагальнити та проаналізувати дані щодо характеристики лектинів (Л), можливих джерел їх виділення, біологічних функцій та механізмів дії на клітини, завдяки яким Л можна застосовувати в діагностиці та терапії при злоякісних новоутвореннях. Передумовами застосування Л в онкології є особливості глікокон’югатів поверхневих мембран
пухлинних клітин (ПК) — посилення процесів фукозилювання і сіалування глікану. Здатність Л взаємодіяти з ізоформами низки пухлинних антигенів дозволяє проводити диференційну діагностику, моніторинг ефективності лікування, прогнозувати перебіг захворювання. Для багатьох Л
продемонстровано in vitro цитотоксичну активність щодо ПК, а також
здатність інгібувати in vivo ріст модельних пухлин. Є відомості щодо клінічної ефективності додаткового застосування Л омели при лікуванні пацієнтів зі злоякісними новоутвореннями молочної залози, тіла матки, легені, шлунка, підшлункової залози. Проаналізована інформація свідчить
про перспективність подальших досліджень щодо використання Л у клінічній онкологічній практиці
Посилання
Boyd WC, Shapleigh E. Specific precipitating activity of plant
agglutinins (lectins). Science 1954; 119: 419.
Podgorskii VS, Kovalenko EA, Karpova IS, et al. Extracellular lectins from Saprophytic strains of bacteria of the genus Bacillus (review). Appl Biochem Microbiol 2014; 50 (3): 256–63
(in Russian).
Coulibaly FS, Youan Bi-BC. Current status of lectin-based
cancer diagnosis and therapy. AIMS Mol Sci 2017; 4 (1): 1–27.
Lam SK, Ng TB. Lectins: prodaction and practical applications. Appl Microbiol Biotechnol 2011; 89: 45–55.
Rudiger H, Gabius HJ. Plant lectins: occurrence, biochemistry, functions and applications. Glycoconj J 2001; 18:
–613.
Varki A, Etzler ME, Cummings RD, et al. Discovery and classification of glycan-binding proteins. In: Essentials of Glycobiology, 2 Eds. A Varki, RD Cummings, JD Esko, et al., eds. New York:
Cold Spring Harbor (Laboratory Press), 2008. 784 p.
Fujimoto Z, Tateno H, Hirabayashi J. Lectin structures: classification based on the 3-D structures. Methods Mol Biol 2014;
: 579–606.
Jayawardena HS, Wang X, Yan M. Classification of lectins by pattern recognition using glyconanoparticles. Anal Chem
; 85: 10277–81.
Lakhtin VM. Lectins in the study of proteins and carbohydrates. Res Science Technol Biotechnol, 1987. 287 p. (in Russian).
Kumar KK, Chandra KL, Sumanthi J, et al. Biological role
of lectins: a review. J Orofac Sci 2012; 4: 20–5.
Hirabayashi J, Tateno H, Shikanai T, et al. The lectin frontier database (LfDB), and Data generation based on frontal affinity chromatography. Molecules 2015; 20: 951–73.
Suzuki T, Amano Y, FujitaM, et al. Purification, characterization, and cDNA cloning of a lectin from the mushroom Pleurocybella porrigens. Biosci Biotechnol Biochem
; 73: 702–9.
Zhang G, Sun J, Wang H, Ng TB. First isolation and characterization of a novel lectin with potent antitumor activity from a
Russula mushroom. Phytomedicine 2010; 17: 775–81.
Zhao JK, Wang HX, Ng TB. Purification and characterization of a novel lectin from the toxic wild mushroom Inocybe umbrinella. Toxicon 2009; 53: 360–6.
Bhat GG, Shetty KN, Nagre NN, et al. Purification, characterization and molecular cloning of a monocot mannosebinding lectin from Remusatia vivipara with nematicidal activity. Glycoconj J 2010; 27: 309–20.
Yan Q, Jiang Z, Yang S, et al. A novel homodimeric lectin
from Astragalus mongholicus with antifungal activity. Arch Biochem Biophys 2005; 442: 72–81.
Podgorskii VS, Kovalenko EA, Simonenko IA. Lectins of
bacteria. Kiev: Naukova Dumka, 1992. 202 p. (in Russian).
Nathan Sharon HL. Lectins: functions. Springer Science
& Business Media, 2007: 333–66.
Varrot A, Basheer SM, Imberty A. Fungal lectins: structure, function and potential applications. Curr Opin Struct Biol
; 23: 678–85.
Bies C, Lehr CM, Woodley JF. Lectin-mediated drug targeting: history and applications. Adv Drug Deliv Rev 2004; 56:
–35.
Santos AFS, da Silva MDC, Napoleao TH, et al. Lectins:
Function, structure, biological properties and potential applications. Curr Top Pept Protein Res 2014; 15: 41–62.
Haab ВВ. Using lectins in biomarker research: addressing the limitations of sensitivity and availability. Proteomics Clin
Appl 2012; 6: 346–50.
Haab ВВ. Antibody-lectin sandwich arrays for biomarker and glycobiology studies. Expert Rev Proteomics 2010; 7: 9–11.
Haab ВВ, Yue T. High-throughput studies of protein glycoforms using antibody-lectin sandwich arrays. Methods Mol Biol
; 785: 223–36.
De Mejia EG, Prisecaru VI. Lectins as bioactive plant
proteins: a potential in cancer treatment. Crit Rev Food Sci Nutr
; 45: 425–45.
Vojdani A. Lectins, agglutinins, and their roles in autoimmune reactivities. Altern Ther Health Med 2015; 21 (Suppl 1): 46–51.
Vincent J, van Buul FJPHB. Health effects of wheat lectins: A review. J Cereal Sci 2014; 59: 112–7.
Mody R, Joshi S, Chaney W. Use of lectins as diagnostic and therapeutic tools for cancer. J Pharmacol Toxicol Methods 1995; 33: 1–10.
Tuccillo FM, de Laurentiis A, Palmieri C, et al. Aberrant
glycosylation as biomarker for cancer: focus on CD43. Bio Med
Res Int 2014; 2014: 1–13.
Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingoglycolipid metabolism. Cancer Res 1996;
(23): 5309–18.
Varki A, Kannagi R, Toole BP. Glycosylation changes in
cancer. In: Essentials of Glycobiology, 2 Eds. A Varki, RD Cummings, JD Esko, et al., eds. New York: Cold Spring Harbor (Laboratory Press), 2008. 784 p.
Munkley J, Elliott DJ. Hallmarks of glycosylation in cancer. Oncotarget 2016; 7 (23): 35478–89.
Aoyagi Y. Molecular discrimination between alpha-fetoprotein from patients with hepatocellular-carcinoma and nonneoplastic liver-diseases by their carbohydrate structures (review). Int
J Oncol 1994; 4: 369–83.
Gnedkova IA, Lisyany NI, Stanetskaya DN, et al. Lectinbinding and tumorigenic properties of glioma C6 cells. Oncology
; 17 (1): 4–11 (in Russian).
Hashim OH, Jayapalan JJ, Lee C-S. Lectins: an effective tool for screening of potential cancer biomarkers. Peer J 2017;
: e3784:
Kang JG, Ko J‐H, Kim Y‐S. Application of cancer‐associated glycoforms and glycan‐binding probes to an in vitro diagnostic multivariate index assay for precise diagnoses of cancer. Proteomics 2016; 16 (24): 3062–72.
Li D, Mallory T, Satomura S. AFP‐L3: a new generation
of tumor marker for hepatocellular carcinoma. Clin Chim Acta
; 313: 15–9.
Oka H, Saito A, Jumada T, et al. Multicenter prospective
analysis of newly diagnosed hepatocellular carcinoma with respect
to the percentage of Lens culinaris agglutinin‐reactive alpha‐fetoprotein. J Gastroenterol Hepatol 2001; 16: 1378–83.
Yi X, Yu S, Bao Y. Alpha-fetoprotein-L3 in hepatocellular
carcinoma: a meta-analysis. Clin Chim Acta 2013; 425: 212–20.
Shimizu K, Taniichi T, Satomura S, et al. Establishment
of assay kits for the determination of microheterogeneities of alpha-fetoprotein using lectin-affinity electrophoresis. Clin Chim
Acta 1993; 214: 3–12.
Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular
carcinoma. HPB (Oxford) 2005; 7: 26–34.
Monira PYK, Mamoru I, Yoriyuki N. Plant lectins in therapeutic and diagnostic cancer research. Int J Plant Biol Res 2015;
: 1–6.
Leerapun A, Suravarapu SV, Bida JP, et al. The utility of
Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol 2007; 5: 394–402.
Kawai K, Kojima T, Miyanaga N, et al. Lectin-reactive alpha-fetoprotein as a marker for testicular tumor activity. Int J Urol
; 12: 284–9.
Llop E, Ferrer-Batalle M, Barrabes S, et al. Improvement
of prostate cancer diagnosis by detecting PSA glycosylation-specific changes. Theranostics 2016; 6 (8): 1190–204.
Dwek MV, Jenks A, Leathem AJ. A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation
of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. Clinica Chimica
Acta 2010; 411: 1935–839.
Reddi AL, Sankaranarayanan K, Arulraj HS, et al. Enzymelinked PNA lectin-binding assay of serum T-antigen in patients
with SCC of the uterine cervix. Cancer Letters 2000; 149: 207–11.
Pervin MKY, Isemura M, Nakamura Y. Plant lectins in
therapeutic and diagnostic cancer research. Int J Plant Biol Res
; 3: 1–6.
Sharon N, Lis H. History of lectins: from hemagglutinins to biological recognition molecules. Glycobiology 2004; 14:
R–62R.
Di Cola A, Frigerio L, Lord JM, et al. Ricin A chain without its partner B chain is degraded after retrotranslocation from
the endoplasmic reticulum to the cytosol in plant cells. Proc Natl
Acad Sci U S A 2001; 98: 14726–31.
Montanaro L, Sperti S, Mattioli A, et al. Inhibition by ricin
of protein synthesis in vitro. Inhibition of the binding of elongation
factor 2 and of adenosine diphosphate-ribosylated elongation factor 2 to ribosomes. Biochem J 1975; 146: 127–31.
Lord MJ, Jolliffe NA, Marsden CJ, et al. Ricin. Mechanisms of cytotoxicity. Toxicol Rev 2003; 22: 53–64.
Zou LB, Zhan JB. Purification and anti-cancer activity
of ricin. Zhejiang Da Xue Xue Bao Yi Xue Ban 2005; 34: 217–9.
Rao PV, Jayaraj R, Bhaskar AS, et al. Mechanism of ricininduced apoptosis in human cervical cancer cells. Biochem Pharmacol 2005; 69: 855–65.
Endo Y, Tsurugi K, Franz H. The site of action of the Achain of mistletoe lectin I on eukaryotic ribosomes. The RNA Nglycosidase activity of the protein. FEBS Lett 1988; 231: 378–80.
Lee CH, Kim JK, Kim HY, et al. Immunomodulating effects of Korean mistletoe lectin in vitro and in vivo. Int Immunopharmacol 2009; 9: 1555–61.
Hajto T, Krisztina F, Ildiko A, et al. Unexpected different binding of mistletoe lectins from plant extracts to immobilized lactose and N-acetylgalactosamine. Anal Chem Insights
; 2: 43–50.
Doser C, Doser M, Hulsen H, et al. Influence of carbohydrates on the cytotoxicity of an aqueous mistletoe drug and of
purified mistletoe lectins tested on human T-leukemia cells. Arzneimittelforschung 1989; 39: 647–51.
Mikeska R, Wacker R, Ami R, et al. Mistletoe lectin I in
complex with galactose and lactose reveals distinct sugar-binding properties. Acta Crystallogr Sect F Struct Biol Cryst Commun 2005; 61: 17–25.
Fu LL, Zhou CC, Yao S, et al. Plant lectins: targeting programmed cell death pathways as antitumor agents. Int J Biochem
Cell Biol 2011; 43: 1442–9.
Thies A, Dautel P, Meyer A, et al. Low-dose mistletoe lectin-I reduces melanoma growth and spread in ascid mouse xenograft model. Br J Cancer 2008; 98: 106–12.
Marvibaigi M, Supriyanto E, Amini N, et al. Preclinical
and clinical effects of mistletoe against breast cancer. Biomed Res
Int 2014; 2014: 1–15.
Lyu SY, Choi SH, Park WB. Korean mistletoe lectin-induced apoptosis in hepatocarcinoma cells is associated with inhibition of telomerase via mitochondrial controlled pathway independent of p53. Arch Pharm Res 2002; 25: 93–101.
Choi SH, Lyu SY, Park WB. Mistletoe lectin induces apoptosis and telomerase inhibition in human A253 cancer
cells through dephosphorylation of Akt. Arch Pharm Res 2004;
: 68–76.
Yau T, Dan X, Ng CC, et al. Lectins with potential for anti-cancer therapy. Molecules 2015; 20: 3791–810.
Zuo Z, Fan H, Wang X, et al. Purification and characterization of a novel plant lectin from Pinellia ternata with antineoplastic activity. Springer Plus 2012; 1: 1–9.
Shi Z, Chen J, Li CY, et al. Antitumor effects of concanavalin A and Sophora flavescens lectin in vitro and in vivo. Acta
Pharmacol Sin 2014; 35: 248–56.
Cavada BS, Silva MTL, Osterne VJS, et al. Canavalia
bonariensis lectin: molecular bases of glycoconjugates interaction and antiglioma potential. Int J Biol Macromolecules 2017;
(2018): 369–78.
Chan YS, Ng TB. A lectin with highly potent inhibitory activity toward breast cancer cells from edible tubers of Dioscorea opposita cv. nagaimo. PLoS One 2013; 8: e54212.
Singh RS, Kaur HP, Kanwar JR. Mushroom lectins as
promising anticancer substances. Curr Protein Pept Sci 2016; 17:
–807.
Hassan MA, Rouf R, Tiralongo E, et al. Mushroom lectins:
specificity, structure and bioactivity relevant to human disease. Int
J Mol Sci 2015; 16: 7802–38.
Yu L, Fernig DG, Smith JA, et al. Reversible inhibition of
proliferation of epithelial cell lines by Agaricus bisporus (edible
mushroom) lectin. Cancer Res 1993; 53: 4627–32.
Zhao C, Sun H, Tong X, et al. An antitumour lectin from
the edible mushroom Agrocybe aegerita. Biochem J 2003; 374:
–7.
Jiang S, Chen Y, Wang M, et al. A novel lectin from Agrocybe aegerita shows high binding selectivity for terminal N-acetylglucosamine. Biochem J 2012; 443: 369–78.
Zheng Shi, Wen-wen Li, Yong Tang, Li-jia Cheng. A novel
molecular model of plant lectin-induced programmed cell death
in cancer. Biol Pharm Bull 2017; 40 (10): 1625–9.
Ziegler R, Grossarth-Maticek R. Individual patient data
meta-analysis of survival and psychosomatic self-regulation from
published prospective controlled cohort studies for long-term therapy of breast cancer patients with a mistletoe preparation (Iscador).
Evid Based Complement Altern Med 2010; 7: 157–66.
Büssing A, Raak C, Ostermann T. Quality of life and related dimensions in cancer patients treated with mistletoes extract
(Iscador): A meta-analysis. Evid Based Complement Altern Med
; 2012: 219402.
Grossarth-Maticek R, Ziegler R. Randomized and nonrandomized prospective controlled cohort studies in matched
pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador). Eur J Med Res 2008;
(3): 107–20.
Bar-Sela G, Wollner M, Hammer L, et al. Mistletoe
as complementary treatment in patients with advanced nonsmall-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. Eur J Cancer 2013; 49
(5): 1058–64.
Kim KC, Yook JH, Eisenbraun J, et al. Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in
patients with gastric carcinoma — a randomized, controlled pilot
study. BMC Complement Altern Med 2012; 12: 172.
Tröger W, Galun D, Reif M, et al. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: A randomised clinical trial on overall survival. Eur
J Cancer 2013; 49: 3788–97.
